Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
For a subsequently approved drug, CMS proposes in 428.202(c)(2) that the payment amount benchmark period would be the first calendar year beginning after the drug's first marketed date, as specified under section 1860D-14B(b)(5)(A) of the Act
The regulations at 425.605(a)(1)(ii)(C) and 425.610(a)(2)(ii)(C) provide that we will use the ACO's historical benchmark expenditures in calculating the weights used to cap ACO risk score growth
The accuracy of our estimate of the information collection burden
The criteria we used to define attribution-eligible beneficiary were aligned with the attribution ( methodologies and rules for our then-contemporaneous Advanced APMs
US$ 25.83
US$ 20.27
US$ 27.11
